Af­ter paint­ing a poor safe­ty pro­file, Pfiz­er and Eli Lil­ly are shoot­ing for a new pain drug OK any­way

Months af­ter an­a­lysts wrote off the NGF pain drug tanezum­ab as a per­pet­u­al los­er, Pfiz­er and Eli Lil­ly have de­cid­ed to push ahead and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA